Axiom Investors LLC DE Invests $20.80 Million in Guardant Health, Inc. $GH

Axiom Investors LLC DE purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 203,642 shares of the company’s stock, valued at approximately $20,800,000.

Other large investors have also modified their holdings of the company. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health in the fourth quarter valued at $27,000. Chesapeake Asset Management LLC acquired a new position in shares of Guardant Health in the fourth quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Guardant Health in the fourth quarter valued at $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health in the fourth quarter valued at $35,000. Finally, Parallel Advisors LLC raised its stake in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Stock Up 4.2%

NASDAQ:GH opened at $130.12 on Wednesday. The firm has a market cap of $17.25 billion, a PE ratio of -38.38 and a beta of 1.61. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $134.28. The company’s 50-day moving average price is $101.04 and its two-hundred day moving average price is $101.54.

Insider Transactions at Guardant Health

In related news, CEO Amirali Talasaz sold 210,000 shares of Guardant Health stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the transaction, the chief executive officer directly owned 1,886,504 shares of the company’s stock, valued at $207,307,924.56. The trade was a 10.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John G. Saia sold 20,000 shares of Guardant Health stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the transaction, the insider directly owned 45,950 shares of the company’s stock, valued at $4,894,134.50. This represents a 30.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 452,238 shares of company stock valued at $51,425,612. 5.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Barclays upped their target price on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Evercore upgraded Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 target price for the company in a research note on Tuesday, June 2nd. TD Cowen restated a “buy” rating on shares of Guardant Health in a research note on Thursday, May 21st. Wells Fargo & Company upped their target price on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. Finally, Leerink Partners upped their target price on Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $139.80.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.